<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To report the efficacy and adverse events with the use of anti-TNFalpha agents in pediatric patients with <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Retrospective, observational clinical case series of patients with <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> refractory to the conventional treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Infliximab and etanercept were the the drugs used </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Thirty patients received anti-TNFalpha therapy: Juvenile Idiopathic <z:hpo ids='HP_0001369'>Arthritis</z:hpo> (18), <z:hpo ids='HP_0011010'>chronic</z:hpo> idiopathic <z:hpo ids='HP_0012122'>anterior uveitis</z:hpo> (2), <z:e sem="disease" ids="C0263666" disease_type="Disease or Syndrome" abbrv="">juvenile dermatomyositis</z:e> (4), Blau syndrome (1), <z:e sem="disease" ids="C0032453" disease_type="Disease or Syndrome" abbrv="">relapsing polychondritis</z:e> (2), <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> (1), and <z:e sem="disease" ids="C0343192" disease_type="Disease or Syndrome" abbrv="">microscopic polyangiitis</z:e> (1) </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty (66,6%) patients used infliximab exclusively, 2 (6,6%) etanercept and 8 (26,6%) both drugs </plain></SENT>
<SENT sid="5" pm="."><plain>The response with infliximab was good in 9 patients, partial in 12 and poor in 5 </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients were not evaluated for the short period of treatment </plain></SENT>
<SENT sid="7" pm="."><plain>The response with etanercept was good in 7, partial in 2 and poor in 1 </plain></SENT>
<SENT sid="8" pm="."><plain>The best benefits were observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JIA</z:e> patients with <z:hpo ids='HP_0005764'>polyarticular arthritis</z:hpo>, psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo> and <z:hpo ids='HP_0100686'>enthesitis</z:hpo>-related <z:hpo ids='HP_0001369'>arthritis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Adverse effects occurred in 15 patients (50%) </plain></SENT>
<SENT sid="10" pm="."><plain>Suspension of the treatment due to adverse events occurred in 7 </plain></SENT>
<SENT sid="11" pm="."><plain>The most frequent infusion reactions with the infliximab were cough and <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Infectious complications occurred in 2 patients receiving etanercept and in 7 receiving infliximab (one <z:hpo ids='HP_0011420'>death</z:hpo> due to <z:hpo ids='HP_0100806'>sepsis</z:hpo>) </plain></SENT>
<SENT sid="13" pm="."><plain>No patients developed <z:e sem="disease" ids="C0041296" disease_type="Disease or Syndrome" abbrv="tb|tbc">tuberculosis</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: Infliximab and etanercept are effective in some subtypes of juvenile idiopathic <z:hpo ids='HP_0001369'>arthritis</z:hpo> and other <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> refractory to conventional therapy </plain></SENT>
<SENT sid="15" pm="."><plain>Although frequent, adverse events could be controlled most of the time </plain></SENT>
</text></document>